Table 1 Demographic and clinical characteristics of the three study groups.

From: Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers

 

NM-NC

GBA NM-MC

LRRK2 NM-MC

p-value

Age

53.55 ± 10.51

52.85 ± 8.81

50.52 ± 7.56

0.44a

Gender (F/M)

18/16

12/14

13/12

0.91b

Handedness

⁃ Right/left/ambidextrous

29/4/2

25/1/0

20/4/1

0.19c

UPDRS-III

0.87 ± 1.26

0.61 ± 1.1

0.76 ± 2.05

0.86a

UPDRS- Total

6.62 ± 5.32

4.50 ± 2.8

5.96 ± 5

0.26a

MOCA

26.50 ± 2.68

26.69 ± 2.56

27.68 ± 2.68

0.28a

UPSIT

31.39 ± 6.95

30.35 ± 7.42

37.12 ± 9.11

0.66a

BDI

2.67 ± 6.21

5.28 ± 5.60

4.56 ± 4.77

0.08a

SCOPA -AUT

7.03 ± 6.21

6.52 ± 7.00

7.18 ± 6.22

0.93a

RBDq

2.00 ± 1.52

1.56 ± 2

1.43 ± 1.85

0.44a

NMS

3.18 ± 3.20

2.80 ± 3.24

2.95 ± 1.92

0.88a

LR

6.33 ± 17.00

11.38 ± 26.23

12.00 ± 26.00

0.57a

⁃ Low (<70) [N, %]

34, 97%

24, 92%

23, 92%

⁃ High (>70) [N,%]

1, 3%

2, 8%

2, 8%

  1. Unless otherwise stated, all values are expressed as mean ± SD.
  2. a1 × 3 ANOVA.
  3. bχ2 test.
  4. cKruskal-Wallis test. H&Y Hohen & Yahr stage, UPDRS Unified Parkinson’s disease rating scale, MOCA Montreal cognitive assessment. UPSIT university of Pennsylvania smell identification test, BDI Beck’s depression inventory, SCOPA-AUT Scale of Outcome in Parkinson’s disease Autonomic Dysfunction questionnaire, RBDq REM sleep behavior disorder questionnaire, NMS nonmotor symptoms questionnaire, LR likelihood ratio.